FDA panel to review Wyeth’s Viviant
Executive Summary
FDA will convene an advisory committee in July to review Wyeth's Viviant (bazedoxifene) for both the treatment and prevention of osteoporosis, the company announces Jan. 31. Wyeth will meet with FDA in February to discuss issues raised in a December "approvable" letter for the prevention indication. During fourth quarter earnings call, Wyeth President-Pharmaceuticals Joe Mahady says agency concerns involve incidents of stroke and thrombotic events as well as data collection at one of the study sites. Firm expects a May FDA action date on the drug to change given the timing of the panel review...